IQVIA Holdings Inc. $IQV Holdings Increased by Quadrant Capital Group LLC

Quadrant Capital Group LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 82.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,651 shares of the medical research company’s stock after acquiring an additional 2,099 shares during the period. Quadrant Capital Group LLC’s holdings in IQVIA were worth $733,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Verdence Capital Advisors LLC acquired a new position in IQVIA during the second quarter worth about $3,612,000. Act Two Investors LLC bought a new position in shares of IQVIA during the 2nd quarter valued at about $26,528,000. Patton Fund Management Inc. acquired a new position in shares of IQVIA in the 2nd quarter worth approximately $231,000. Shell Asset Management Co. raised its holdings in shares of IQVIA by 78.7% in the 2nd quarter. Shell Asset Management Co. now owns 9,256 shares of the medical research company’s stock worth $1,459,000 after purchasing an additional 4,077 shares in the last quarter. Finally, Heritage Investors Management Corp lifted its stake in IQVIA by 10.5% during the second quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after purchasing an additional 9,909 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $228.48 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a market cap of $38.91 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 2.58 and a beta of 1.37. The business has a fifty day simple moving average of $210.88 and a 200-day simple moving average of $184.69.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the prior year, the business earned $2.84 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IQV shares. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Friday. Robert W. Baird set a $258.00 target price on IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. boosted their target price on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Cowen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Finally, Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $241.44.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.